About

Roberto Bravo, PhD, is Head of Pharmaceutical Development at Tillotts Pharma. He leads a team of project leaders and scientists responsible for the development of new drug products for the effective treatment of inflammatory bowel diseases. Prior to Tillotts Pharma, Dr Bravo’s career started 20 years ago, when he joined F Hoffmann-La Roche and thereafter Actelion Pharmaceuticals, engaged in the physicochemical characterisation of new active compounds and in formulations to improve their oral bioavailability.